NYSE:CRL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Charles River Laboratories International

Market Cap

US$20.4b

Last Updated

2021/07/30 00:53 UTC

Data Sources

Company Financials +

Executive Summary

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. More Details


Snowflake Analysis

Solid track record with reasonable growth potential.


Similar Companies

Share Price & News

How has Charles River Laboratories International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CRL is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: CRL's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

3.1%

CRL

2.3%

US Life Sciences

0.8%

US Market


1 Year Return

101.4%

CRL

44.3%

US Life Sciences

37.5%

US Market

Return vs Industry: CRL exceeded the US Life Sciences industry which returned 43.5% over the past year.

Return vs Market: CRL exceeded the US Market which returned 36.5% over the past year.


Shareholder returns

CRLIndustryMarket
7 Day3.1%2.3%0.8%
30 Day9.1%3.5%1.0%
90 Day22.0%12.1%3.8%
1 Year101.4%101.4%44.5%44.3%39.7%37.5%
3 Year219.6%219.6%115.9%114.8%64.4%54.1%
5 Year366.0%366.0%233.3%229.4%124.9%100.0%

Long-Term Price Volatility Vs. Market

How volatile is Charles River Laboratories International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Charles River Laboratories International undervalued compared to its fair value and its price relative to the market?

53.79x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CRL ($405.52) is trading above our estimate of fair value ($290.48)

Significantly Below Fair Value: CRL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CRL is poor value based on its PE Ratio (53.8x) compared to the US Life Sciences industry average (48.5x).

PE vs Market: CRL is poor value based on its PE Ratio (53.8x) compared to the US market (18.3x).


Price to Earnings Growth Ratio

PEG Ratio: CRL is poor value based on its PEG Ratio (2.9x)


Price to Book Ratio

PB vs Industry: CRL is overvalued based on its PB Ratio (9.3x) compared to the US Life Sciences industry average (6x).


Future Growth

How is Charles River Laboratories International forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

18.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRL's forecast earnings growth (18.3% per year) is above the savings rate (2%).

Earnings vs Market: CRL's earnings (18.3% per year) are forecast to grow faster than the US market (15% per year).

High Growth Earnings: CRL's earnings are forecast to grow, but not significantly.

Revenue vs Market: CRL's revenue (10% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: CRL's revenue (10% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CRL's Return on Equity is forecast to be high in 3 years time (21.1%)


Past Performance

How has Charles River Laboratories International performed over the past 5 years?

19.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CRL has high quality earnings.

Growing Profit Margin: CRL's current net profit margins (12.3%) are higher than last year (9.1%).


Past Earnings Growth Analysis

Earnings Trend: CRL's earnings have grown by 19.6% per year over the past 5 years.

Accelerating Growth: CRL's earnings growth over the past year (51.4%) exceeds its 5-year average (19.6% per year).

Earnings vs Industry: CRL earnings growth over the past year (51.4%) exceeded the Life Sciences industry 34.8%.


Return on Equity

High ROE: CRL's Return on Equity (17.1%) is considered low.


Financial Health

How is Charles River Laboratories International's financial position?


Financial Position Analysis

Short Term Liabilities: CRL's short term assets ($1.4B) exceed its short term liabilities ($803.4M).

Long Term Liabilities: CRL's short term assets ($1.4B) do not cover its long term liabilities ($2.8B).


Debt to Equity History and Analysis

Debt Level: CRL's debt to equity ratio (98.2%) is considered high.

Reducing Debt: CRL's debt to equity ratio has reduced from 103.4% to 98.2% over the past 5 years.

Debt Coverage: CRL's debt is well covered by operating cash flow (29.8%).

Interest Coverage: CRL's interest payments on its debt are well covered by EBIT (4.8x coverage).


Balance Sheet


Dividend

What is Charles River Laboratories International current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Jim Foster (70 yo)

29.5yrs

Tenure

US$13,483,411

Compensation

Mr. James C. Foster, J.D., has been the Chairman of the Board at Charles River Laboratories, Inc. (CRL) since 2000 and has been its Chief Executive Officer and President since 1992 and 1991 respectively. M...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD13.48M) is about average for companies of similar size in the US market ($USD11.27M).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CRL's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: CRL's board of directors are seasoned and experienced ( 10.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CRL insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Charles River Laboratories International, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Charles River Laboratories International, Inc.
  • Ticker: CRL
  • Exchange: NYSE
  • Founded: 1947
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.379b
  • Shares outstanding: 50.25m
  • Website: https://www.criver.com

Number of Employees


Location

  • Charles River Laboratories International, Inc.
  • 251 Ballardvale Street
  • Wilmington
  • Massachusetts
  • 1887
  • United States

Listings


Biography

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/30 00:53
End of Day Share Price2021/07/29 00:00
Earnings2021/03/27
Annual Earnings2020/12/26


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.